Verona Pharma Ltd - Company Profile
Powered by 
All the sales intelligence you need on Verona Pharma Ltd in one solution.
- Save hours of research time with a comprehensive
Sales Intelligence Solution.
- Understand how Verona Pharma Ltd fits into your total
addressable market and Ideal Customer Profile.
- Gain competitive edge with triggers that tell you
when and how to engage with Verona Pharma Ltd.
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
Business Description
Verona Pharma Ltd (Verona Pharma), a subsidiary of Merck & Co Inc, develops and commercializes innovative therapies for chronic respiratory diseases with significant unmet medical needs. The company's lead product candidate, ensifentrine, is a first-in-class, inhaled dual inhibitor targeting phosphodiesterase 3 and 4 (PDE3 and PDE4). This novel molecule combines bronchodilator and non-steroidal anti-inflammatory activities.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
R&D Overview
Verona Pharma is actively advancing its research and development efforts for ensifentrine, a dual-action bronchodilator and anti-inflammatory drug aimed at treating a wide range of conditions such as chronic obstructive pulmonary disease (COPD), cystic fibrosis (CF), and asthma. The company's patent portfolio comprises eleven issued US patents, seven pending US patent applications (including four US provisional applications), seventy-nine issued foreign patents, and seventy-five pending foreign applications (including six international PCT applications). This portfolio encompasses claims related to respirable formulations of ensifentrine, its crystalline forms, and combinations with specific respiratory drugs. Additionally, it includes claims for various salts of ensifentrine, its use in treating cystic fibrosis, non-cystic fibrosis bronchiectasis, and other respiratory disorders, and methods for its production.
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer